For example, our group recently reported that transcripts of the MYCN gene, the strongest molecular risk of neuroblastoma, were detectable in LEVs isolated from patient-derived bone marrow plasma, where the presence and absence of MYCN-LEVs were associated with MYCN-amplification status and treatment–relapse states [46]. This evidence concerns the gene MYCN and neuroblastoma.